

## This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Cancer	Cyclin-dependent kinase 4 (CDK4); cyclin D3 (CCND3)	Structural determination of the CDK4-CCND3 complex could be useful for identifying CDK4 inhibitors to treat cancer. The structure of the CDK4-CCND3 complex had an inactive CDK4 conformation that differed from previously described CDK-cyclin complexes, thus suggesting a new target for designing selective CDK4 inhibitors. Next steps include structure-based drug design using the CDK4-CCND3 structure. PD332991, a selective CDK4 inhibitor from Onyx Pharmaceuticals Inc. and Pfizer Inc., is in Phase I trials to treat cancer.	Unpatented; licensing status not applicable	Takaki, T. <i>et al. Proc. Natl. Acad. Sci. USA</i> ; published online Feb. 16, 2009; doi:10.1073/pnas.0809674106 <b>Contact:</b> Martin E.M. Noble, University of Oxford, Oxford, U.K. e-mail: <a href="mailto:martin.noble@bioch.ox.ac.uk">martin.noble@bioch.ox.ac.uk</a>
<p><b>SciBX 2(8); doi:10.1038/scibx.2009.308</b>  <b>Published online Feb. 26, 2009</b></p>				